Related Experiment Video
Updated: Feb 10, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Impact of pharmacogenomics on clinical practice in oncology
1Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA. smarsh@im.wustl.edu
Abstract:
Multiple drug strategies for many cancer types are now readily available and there is a clear need for tools to inform decision making on therapy selection. Although there is still a long way to go before pharmacogenomics achieves the goal of individualized selection of cancer treatment, promising progress is being made. Genetic testing for thiopurine methyltransferase (TPMT) variant alleles in patients prior to mercaptopurine administration, and for UGT1A1*28 in patients prior to administration of irinotecan therapy, along with the instigation of genotype-guided clinical trials (e.g. TYMS) are important advances in cancer pharmacogenomics. Markers for the toxicity and efficacy of many oncology drugs remain unknown; however, the examples highlighted here suggest progress is being made towards the incorporation of pharmacogenomics into clinical practice in oncology.
Insights
Pharmacogenomics is advancing cancer treatment by guiding drug selection. Genetic testing for TPMT and UGT1A1 variants, alongside genotype-guided trials, improves personalized oncology therapy decisions.
Area of Science:
- Pharmacogenomics
- Oncology
- Clinical Pharmacology
Background:
- Multiple drug strategies are available for cancer treatment, necessitating tools for informed therapy selection.
- Individualized cancer treatment selection via pharmacogenomics is a long-term goal with significant ongoing progress.
Purpose of the Study:
- To highlight advances in cancer pharmacogenomics and their incorporation into clinical practice.
- To discuss the role of genetic testing in optimizing cancer drug therapy selection and patient outcomes.
Main Methods:
- Review of current pharmacogenomic applications in oncology.
- Examples include genetic testing for thiopurine methyltransferase (TPMT) and UGT1A1*28 variant alleles.
- Mention of genotype-guided clinical trials, such as those involving TYMS.
Main Results:
- Genetic testing for TPMT variants before mercaptopurine and UGT1A1*28 before irinotecan are key advances.
- Genotype-guided clinical trials demonstrate progress in applying pharmacogenomics.
- Despite unknown markers for many drugs, progress is evident in integrating pharmacogenomics into oncology.
Conclusions:
- Pharmacogenomics shows significant promise for individualized cancer treatment selection.
- Current advances in genetic testing and clinical trials are paving the way for routine pharmacogenomic application in oncology.
- Further research is needed to identify more genetic markers for drug toxicity and efficacy.
Related Concept Videos
Impact of Groups on Individuals
Impact of Groups on Groups
Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
Equivalent Circuits for Practical Transformers
In a practical transformer, each winding exhibits resistance and leakage reactance. The...

